These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11407710)

  • 1. Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs?
    Ward MM
    Arthritis Rheum; 2001 Jun; 44(6):1467-9. PubMed ID: 11407710
    [No Abstract]   [Full Text] [Related]  

  • 2. Premature mortality in patients with rheumatoid arthritis: evolving concepts.
    Pincus T; Sokka T; Wolfe F
    Arthritis Rheum; 2001 Jun; 44(6):1234-6. PubMed ID: 11407680
    [No Abstract]   [Full Text] [Related]  

  • 3. "5D" Outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial disease modifying antirheumatic drug therapy.
    Capell H; McCarey D; Madhok R; Hampson R
    J Rheumatol; 2002 Oct; 29(10):2099-105. PubMed ID: 12375318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rheumatoid arthritis shortens life].
    Myllykangas-Luosujärvi R; Aho K; Kautiainen H; Isomäki H
    Duodecim; 1995; 111(13):1209-15. PubMed ID: 9221228
    [No Abstract]   [Full Text] [Related]  

  • 5. Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis.
    Nikolaisen C; Rekvig OP; Nossent HC
    Scand J Rheumatol; 2005; 34(4):269-76. PubMed ID: 16195159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness.
    Wolfe F; Michaud K
    Rheumatology (Oxford); 2005 Dec; 44 Suppl 4():iv18-iv22. PubMed ID: 16306476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
    van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Ewals JA; Han KH; Hazes JM; Kerstens PJ; Peeters AJ; van Zeben D; Breedveld FC; Huizinga TW; Dijkmans BA; Allaart CF
    Arthritis Rheum; 2009 Jan; 61(1):4-12. PubMed ID: 19116965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96.
    Gordon P; West J; Jones H; Gibson T
    J Rheumatol; 2001 Nov; 28(11):2409-15. PubMed ID: 11708411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress toward the cure of rheumatoid arthritis? The BeSt study.
    Weisman MH
    Arthritis Rheum; 2005 Nov; 52(11):3326-32. PubMed ID: 16258928
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
    Ideguchi H; Ohno S; Ishigatsubo Y
    J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Hider SL; Bruce IN; Silman AJ; Symmons DP
    J Rheumatol; 2005 Jan; 32(1):6-10. PubMed ID: 15630715
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
    Choi HK; Seeger JD; Kuntz KM
    Am J Med; 2004 May; 116(9):621-9. PubMed ID: 15093759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study.
    Sihvonen S; Korpela M; Mustonen J; Huhtala H; Karstila K; Pasternack A
    J Rheumatol; 2006 Sep; 33(9):1740-6. PubMed ID: 16881099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?
    Kremer J
    Arthritis Rheum; 2005 Oct; 53(5):636-8. PubMed ID: 16208649
    [No Abstract]   [Full Text] [Related]  

  • 16. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
    Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B;
    J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Nijmegen inception cohort of early rheumatoid arthritis.
    Welsing PM; van Riel PL
    J Rheumatol Suppl; 2004 Mar; 69():14-21. PubMed ID: 15053447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of actarit combination therapy in patients with active rheumatoid arthritis resistant to gold agents].
    Sakurai T; Iso T; Inoue H; Sano K; Takeuchi K; Takagishi K
    Ryumachi; 2001 Jun; 41(3):635-45. PubMed ID: 11505513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic strategies for rheumatoid arthritis.
    Smolen JS; Steiner G
    Nat Rev Drug Discov; 2003 Jun; 2(6):473-88. PubMed ID: 12776222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community-based evaluation of etanercept in patients with rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Wang EC; Khalidi N
    J Rheumatol; 2006 Apr; 33(4):665-70. PubMed ID: 16568506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.